Orexo in brief
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners.
- Developed four commercial pharmaceutical products with worldwide approval
- Addresses unmet need within the growing space of opioid use disorder (OUD) and adjacent diseases/conditions
- Profitable US Commercial operations covering states in the US with highest prevalence of OUD
- Expanding pipeline based on AmorphOX® - a first-class, powder-based technology, enabling outstanding bio-availability and stability of both small and large molecules.
Orexo’s business model is integrated and includes the entire value chain, from the innovation phase to product access and commercialization. Cross-functional teams bring together specialist competencies to evaluate new development projects funded by revenues from the company’s own sales or out-licensing of products and development projects.